Clinical trial
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V…
NCT00062699 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00062699 |
|---|---|
| Title | Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis |
| Official title | A Phase IV, Prospective, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Multi-Center Study to Evaluate the Survival Benefits of Zemplar Relative to Calcijex in Subjects With Stage V Chronic Kidney Disease on Hemodialysis |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | End-Stage Kidney Disease |
| Intervention type | Drug |
| Interventions | Zemplar (paricalcitol injection), Calcijex |
| Enrollment | 2,200 |
| Start date | Apr 1, 2003 |
| First posted | Jun 13, 2003 |
| Last update posted | Aug 2, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: